A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

• Status: Terminated
• Trial end date: 2018-01-18

Summary

Patients suffering from histologically or cytologically confirmed stage IV lung or breast cancer with progressive or recurrent brain metastases after prior external beam radiotherapy will receive treatment with cabazitaxel until progression of brain metastases (BM) or unacceptable toxicity.

• Phase: Phase 2

Details

• Lead Sponsor: AIO-Studien-gGmbH
• Collaborators: ClinAssess GmbH; Sanofi